What this is
- How it works
- How it works isn't classified yet
- Tested for
- Lower Back Pain
- Main trialPhase 1
- “This clinical study is being conducted to evaluate the safety, tolerability, plasma pharmacokinetics and efficacy of an investigational drug called CNTX-3001. This Phase 1 study is the first time that CNTX-3001 will be given to people (first-in-human study). The study is being done to evaluate whether CNTX-3001, given into the intrathecal space by lumbar puncture, can be administered safely to participants who have been diagnosed with intractable chronic moderate to severe low back pain and who have not responded well to other treatments in the past. CNTX-3001 is a novel, non-opioid small…”In the company’s words, NCT07122453 on ClinicalTrials.gov
Other drugs for Lower Back Pain
- IDCTDiscGenics, Inc. · Phase 3
- LY4065967Eli Lilly · Phase 2
- Lumbar InjectionsR3 Stem Cell · Phase 1
Coming up1
- Jan 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Jan 2027 | Safety and PK of Intrathecal CNTX-3001 for Intractable Chronic Low Back Pain |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026